Will a domestic version of platinib be launched in China in 2024?

Pralsetinib (Pralsetinib), trade name Gavreto, is a receptor tyrosine kinase RET (Rearranged during Transfection inhibitor (TKI), it is an oral, once-daily, potent and highly selective drug that can be used to treat non-small cell lung cancer and thyroid cancer related to a rare genetic mutation, that is, RET gene fusion-positive tumors.

The development of Platinib was completed byBlueprint Medicines. As for whether a domestic version of Platinib will be launched in China, there is currently no clear information. Platinib capsules have been approved by the China National Medical Products Administration and are used to treat adult patients with RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). However, it is understood that CStone Pharmaceuticals has obtained the exclusive development and commercialization authorization of the drug in Greater China. This means that in the country, patients are expected to obtain the domestic version of platinib.

The main component of Platinib is Platinib, and its emergence provides a new treatment option for patients with RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Although Platinib has been approved and launched in China, it is still necessary to follow the doctor's advice and guidance during use to ensure the effectiveness and safety of the drug. Its common packaging specifications are 100mg*60 pills and 100mg*120 pills, but the price is relatively high. A box may exceed more than 20,000 yuan, and the price in some areas is even as high as 60,000 yuan.

In general, platinib is a highly efficient and selectiveRET inhibitor that has important clinical value in the treatment of RET gene fusion-positive cancer patients.